Advertisement

Pharmacokinetic Analysis of Malignant Pleural Mesothelioma—Initial Results of Tumor Microcirculation and its Correlation to Microvessel Density (CD-34)

      Rationale and Objectives

      Malignant mesothelioma (MM) of the pleura is an aggressive and often fatal neoplasm. Because MM frequently demonstrates marked angiogenesis, it may be responsive to antiangiogenic therapy, but effective methods for selecting and monitoring of patients are further needed. We employed dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and quantitative immunohistochemistry (IHC) to characterize the microvascularity of MM using both a physiologic and ultrastructural method.

      Materials and Methods

      Nineteen patients diagnosed with MM were enrolled and DCE-MRI was performed before antiangiogenic treatment. For each patient, tumor regions were characterized by their DCE-MRI–derived pharmacokinetic parameters (Amp, kep, kel), which were also compared to those of normal tissue (aorta, liver, spleen, and muscle). In addition, quantitative IHC of representative samples was performed with CD-34 staining to compare the calculated microvessel density (MVD) results with DCE-MRI results.

      Results

      MM demonstrated markedly abnormal pharmacokinetic properties compared with normal tissues. Among the parameters tested, Amp was significantly different in MM (P ≤ .001) compared to normal organs. Despite the observation that the MVD of mesotheliomas in this series was high compared to other tumors, DCE-MRI pharmacokinetic parameters had a moderately positive correlation with MVD (r = 0.5).

      Conclusions

      DCE-MRI and IHC can be used in patients with MM to visualize tumor microvascularity and to characterize tumor heterogeneity. DCE-MRI and IHC results positively correlated, though moderately, but these two methods present as essential tumor biomarkers. This multimodal characterization may be useful in selecting possible tumor subtypes that would benefit from antiangiogenic therapy.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Academic Radiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kayser K.
        • Becker C.
        • Seeberg N.
        • et al.
        Quantitation of asbestos and asbestos-like fibers in human lung tissue by hot and wet ashing, and the significance of their presence for survival of lung carcinoma and mesothelioma patients.
        Lung Cancer. 1999; 24: 89-98
        • Kayser K.
        • Bohm G.
        • Blum S.
        • et al.
        Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
        J Pathol. 2001; 193: 175-180
        • Sugarbaker D.J.
        • Flores R.M.
        • Jaklitsch M.T.
        • et al.
        Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
        J Thorac Cardiovasc Surg. 1999; 117: 54-63
        • Choyke P.L.
        • Dwyer A.J.
        • Knopp M.V.
        Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.
        J Magn Reson Imaging. 2003; 17: 509-520
        • Knopp M.V.
        • Weiss E.
        • Sinn H.P.
        • et al.
        Pathophysiologic basis of contrast enhancement in breast tumors.
        J Magn Reson Imaging. 1999; 10: 260-266
        • Nosas-Garcia S.
        • Moehler T.
        • Wasser K.
        • et al.
        Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers.
        J Magn Reson Imaging. 2005; 22: 154-162
        • Hylton N.
        Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.
        J Clin Oncol. 2006; 24: 3293-3298
        • Hawighorst H.
        • Knopp M.V.
        • Debus J.
        • et al.
        Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results.
        J Magn Reson Imaging. 1998; 8: 783-788
        • Knopp M.V.
        • Tengg-Kobligk H.
        • Choyke P.L.
        Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring.
        Mol Cancer Ther. 2003; 2: 419-426
        • Padhani A.R.
        • Gapinski C.J.
        • Macvicar D.A.
        • et al.
        Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA.
        Clin Radiol. 2000; 55: 99-109
        • Mayr N.A.
        • Hawighorst H.
        • Yuh W.T.
        • et al.
        MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome.
        J Magn Reson Imaging. 1999; 10: 267-276
        • Butchart E.G.
        • Ashcroft T.
        • Barnsley W.C.
        • et al.
        Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura.
        Thorax. 1976; 31: 15-24
        • Butchart E.G.
        Surgery of mesothelioma of the pleura.
        in: Roth J.A. Ruckdeschel J.C. Weinseinberger T.H. Thoracic oncology. WB Saunders Co, Philadelphia, PA1989: 566-583
        • Hoffmann U.
        • Brix G.
        • Knopp M.V.
        • et al.
        Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
        Magn Reson Med. 1995; 33: 506-514
        • Brix G.
        • Semmler W.
        • Port R.
        • et al.
        Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.
        J Comput Assist Tomogr. 1991; 15: 621-628
        • Kayser K.
        • Trott J.
        • Bohm G.
        • et al.
        Localized fibrous tumors (LFTs) of the pleura: clinical data, asbestos burden, and syntactic structure analysis applied to newly defined angiogenic/growth-regulatory effectors.
        Pathol Res Pract. 2005; 201: 791-801
        • Kayser K.
        • Gabius H.J.
        The application of thermodynamic principles to histochemical and morphometric tissue research: principles and practical outline with focus on the glycosciences.
        Cell Tissue Res. 1999; 296: 443-455
        • Zou K.H.
        • Tuncali K.
        • Silverman S.G.
        Correlation and simple linear regression.
        Radiology. 2003; 227: 617-622
        • Szoke T.
        • Kayser K.
        • Baumhakel J.D.
        • et al.
        Prognostic significance of microvascularization in cases of operated lung cancer.
        Eur J Cardiothorac Surg. 2005; 27: 1106-1111
        • Kayser G.
        • Baumhakel J.D.
        • Szoke T.
        • et al.
        Vascular diffusion density and survival of patients with primary lung carcinomas.
        Virchows Arch. 2003; 442: 462-467
        • Galbraith S.M.
        • Rustin G.J.
        • Lodge M.A.
        • et al.
        Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
        J Clin Oncol. 2002; 20: 3826-3840
        • Sorensen A.G.
        Magnetic resonance as a cancer imaging biomarker.
        J Clin Oncol. 2006; 24: 3274-3281
        • Folkman J.
        Tumor angiogenesis: therapeutic implications.
        N Engl J Med. 1971; 285: 1182-1186
        • Martincich L.
        • Montemurro F.
        • De Rosa G.
        • et al.
        Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
        Breast Cancer Res Treat. 2004; 83: 67-76
        • Weidner N.
        • Semple J.P.
        • Welch W.R.
        • et al.
        Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma.
        N Engl J Med. 1991; 324: 1-8
        • Mattern J.
        • Koomagi R.
        • Volm M.
        Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
        Br J Cancer. 1996; 73: 931-934
        • Kumar-Singh S.
        • Vermeulen P.B.
        • Weyler J.
        • et al.
        Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma.
        J Pathol. 1997; 182: 211-216
        • Ohta Y.
        • Shridhar V.
        • Bright R.K.
        • et al.
        VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.
        Br J Cancer. 1999; 81: 54-61